Beyond Type 1 Funding Model


One hundred percent of operational expenses of Beyond Type 1 are covered by our Executive Board, Founding Friends, and select corporate partners in an effort to maximize the impact of community support and enhance transparency. One hundred percent of donations from the community directly fund Beyond Type 1’s portfolio of curated programs and grants, making a direct and immediate impact in the lives of people living with Type 1 diabetes. Often donations are earmarked for individual programs within our portfolio, and when general donations are received by Beyond Type 1 they go solely to T1D-related programs; all T2D programs are funded through corporate support or earmarked donations. This policy allows us to engage with partners that further our mission to improve the lives of those impacted by diabetes, and to educate, advocate, and fund a cure for Type 1.

To avoid a potential conflict of interest specifically around the issue of insulin pricing, Beyond Type 1 maintains an organizational policy not to accept cash contributions from insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi. To date, one exception to this organizational policy has been approved by the Board of Directors: in 2019, we have partnered with Eli Lilly to raise awareness about severe hypoglycemia and Glucagon for all people with diabetes, as we believe the issue has the potential to save lives.

The Beyond Type 1 Board of Directors further abide by a Conflict of Interest policy that is reviewed annually. The Beyond Type 1 Conflict of Interest policy, along with annual tax filings and audited financial statements are available by request. Questions about this policy should be directed to

Beyond Type 1 is a 501(c)(3) tax-exempt nonprofit organization, under charitable ID #47-3336640.